ABS-1230

DRUG2 trials

Sponsors

Actio Biosciences, Inc.

Conditions

KCNT1-Related Epilepsy

Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

RecruitingNCT07156201

Actio Biosciences, Inc.KCNT1-Related Epilepsy

Start: 2025-08-28End: 2026-12-01Target: 92Updated: 2026-08-07

Phase 2

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

RecruitingNCT07600736

Actio Biosciences, Inc.KCNT1-Related Epilepsy

Start: 2026-05-18End: 2028-01-01Target: 55Updated: 2026-08-07